Sovargen Dosed First Patient in Paxalisib Trial
The Phase 1b/2a study tests a dual inhibitor therapy for patients with rare, treatment-resistant neurological disorders.
Updated on Sept. 22, 2026 in Biotech
Live Poll
Do you believe the medical industry is prioritizing the development of treatments for rare diseases enough?
Sovargen Co. has administered the first dose of paxalisib to a patient in a Phase 1b/2a clinical trial targeting focal cortical dysplasia type 2 and tuberous sclerosis complex. This milestone triggered a $2 million payment to Kazia Therapeutics under an existing licensing agreement.
Why it matters
These conditions lack approved pharmacological treatments and are driven by somatic mutations in the PI3K/Akt/mTOR pathway that cause treatment-resistant seizures. Testing paxalisib marks a move toward addressing the biological root of these mTORopathy-related epilepsies.
Paxalisib is an oral, brain-penetrant molecule that functions as a dual inhibitor of PI3K and mTOR. These enzymes are critical components of the cellular signaling pathways involved in growth and proliferation.
The players
Sovargen Co.
A Korea-based pharmaceutical firm focused on the development and commercialization of therapeutics for mTORopathy-related epilepsies.
Kazia Therapeutics
A Sydney-based oncology-focused biotechnology company developing small-molecule drug candidates for brain-related diseases.
The details
The drug targets the PI3K/Akt/mTOR pathway, a series of proteins that regulate cell growth and survival. By inhibiting these enzymes, paxalisib aims to dampen the overactive signaling caused by somatic mutations in focal cortical dysplasia type 2 and tuberous sclerosis complex. Because the drug is brain-penetrant, it is designed to cross the blood-brain barrier to reach neurological targets directly.
Timeline
March 2024: Kazia Therapeutics and Sovargen Co. signed an exclusive licensing agreement.
September 22, 2026: The first patient was dosed in the clinical trial.
The Tech Race
This development follows a pattern set by PI3K/Akt/mTOR pathway research, which has increasingly targeted neurological conditions driven by somatic mutations. The trial represents a shift in applying established oncology-based inhibitors to rare, non-cancerous neurological disorders.
This trial currently affects only adult patients enrolled in the study as it remains in early clinical development. Future availability of the therapy depends entirely on the successful completion of subsequent trial phases and regulatory approval.
The takeaway
The progression of paxalisib into human trials offers a new mechanism to address conditions that currently have no approved therapies. Investors and the medical community should monitor future milestone achievements and clinical trial data for efficacy results in these rare patient populations.
Further reading
For more on the current landscape of experimental neurological therapies, visit our Biotech section.
Live Poll
Do you believe the medical industry is prioritizing the development of treatments for rare diseases enough?
